 To compare the efficacy of BF2.649 over placebo 12 week Double-Blind Phase and assess the long term safety and the efficacy maintenance9 months Open-Label Extension Phase of BF2.649 in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinsons Disease. 